Literature DB >> 6773632

Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats.

P H Reitsma, O L Bijvoet, H Verlinden-Ooms, L J van der Wee-Pals.   

Abstract

Dose-related effects of APD on bone metabolism and Ca homeostasis were studied in rats. The experimental approach consisted of longitudinal and cross-sectional observations, aiming at a kinetic interpretation. Bone and cartilage resorption was inhibited with 2--8 days at doses between 0.16 and 16 mumol/kg body weight/day. This was followed by changes in bone apposition that needed at least 23 days for a maximal effect. The time lag created a transient dissociation between resorption and apposition resulting in excess Ca and P retention, adding to increased metaphyseal bone mass. At high doses of APD (greater than or equal to 40 mumol/kg/day)the mineral content of new matrix decreased, associated with impairment of longitudinal growth of long bones. It is concluded that the lower doses of APD inhibited resorption of bone and cartilage, possibly by physicochemical stabilization of bone mineral, whereas the effect on bone apposition was due to a cellular homeostatic mechanism. Inhibition of growth and of matrix calcification, requiring much higher doses, may be due to a direct, toxic effect on bone cells. The modes of action of APD are discussed in relation to EHDP and Cl2MDP.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773632     DOI: 10.1007/bf02408534

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  33 in total

1.  A modification of the masson trichrome technique for routine laboratory purposes.

Authors:  J Goldner
Journal:  Am J Pathol       Date:  1938-03       Impact factor: 4.307

2.  Diphosphonate treatment of Paget's disease of bone. A correlated metabolic, calcium kinetic and morphometric study.

Authors:  J Guncaga; T Lauffenburger; C Lentner; M A Dambacher; H G Haas; H Fleisch; A J Olah
Journal:  Horm Metab Res       Date:  1974-01       Impact factor: 2.936

3.  Effect of diphosphonates and calcitonin on the chemistry and quantitative histology of rat bone.

Authors:  R G Russell; A M Kislig; P A Casey; H Fleisch; J Thornton; R Schenk; D A Williams
Journal:  Calcif Tissue Res       Date:  1973-03-12

4.  Effect of disodium ethane-1-hydroxy-1, 1-diphosphonate on bone formation.

Authors:  W R King; M D Francis; W R Michael
Journal:  Clin Orthop Relat Res       Date:  1971       Impact factor: 4.176

5.  Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

Authors:  R D Altman; C C Johnston; M R Khairi; H Wellman; A N Serafini; R R Sankey
Journal:  N Engl J Med       Date:  1973-12-27       Impact factor: 91.245

6.  Spleen cells transmit osteopetrosis in mice.

Authors:  D G Walker
Journal:  Science       Date:  1975-11-21       Impact factor: 47.728

7.  Light microscopic and ultrastructural observations on the short-term effects of ethylene-1-hydroxy-1, 1-diphosphonate (EHDP) on rat tibia epiphysis.

Authors:  A Larsson; S E Larsson
Journal:  Acta Pathol Microbiol Scand A       Date:  1976-01

8.  The comparative effects of dichloromethylene diphosphonate (C12MDP) and ethane-1-hydroxy-1,1-diphosphonate (EHDP) on growth and modeling of the rat tibia.

Authors:  S C Miller; W S Jee
Journal:  Calcif Tissue Res       Date:  1977-10-20

9.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

10.  The inhibitory effect of new diphosphonic acids on aortic and kidney calcification in vivo.

Authors:  M Potokar; M Schmidt-Dunker
Journal:  Atherosclerosis       Date:  1978-08       Impact factor: 5.162

View more
  40 in total

1.  Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.

Authors:  H Cohen; V Solomon; I S Alferiev; E Breuer; A Ornoy; N Patlas; N Eidelman; G Hägele; G Golomb
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

2.  Hyperostosis induced by the bisphosphonate (2-PEBP) in the oophorectomized rat.

Authors:  C Movsowitz; S Epstein; M Fallon; F Ismail; S Thomas
Journal:  Calcif Tissue Int       Date:  1990-03       Impact factor: 4.333

Review 3.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  Role of oral pamidronate in preventing bone loss in postmenopausal women.

Authors:  B Lees; S W Garland; C Walton; D Ross; M I Whitehead; J C Stevenson
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

5.  Different schedules of administration of (3 amino-1-hydroxypropylidene)-1, 1 bisphosphonate induce different changes in pig bone remodeling.

Authors:  M C de Vernejoul; A Pointillart; C Bergot; J Bielakoff; C Morieux; A M Laval Jeantet; L Miravet
Journal:  Calcif Tissue Int       Date:  1987-03       Impact factor: 4.333

6.  "Zebra Stripe" Sign and "Bone in Bone" Sign in Cyclical Bisphosphonate Therapy.

Authors:  Partha Pratim Chakraborty; Sugata Narayan Biswas; Shinjan Patra; Gouranga Santra
Journal:  J Clin Diagn Res       Date:  2017-02-01

7.  The effects of hydrocortisone, parathyroid hormone and the bisphosphonate, APD, on bone resorption in neonatal mouse calvaria.

Authors:  I R Reid; J M Katz; H K Ibbertson; D H Gray
Journal:  Calcif Tissue Int       Date:  1986-01       Impact factor: 4.333

Review 8.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

9.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

10.  Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  P H Reitsma; O L Bijvoet; M Potokar; L J van der Wee-Pals; M M van Wijk-van Lennep
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.